Affiliation: Christie Hospital
- The role of chemotherapy (CT) and supportive care (SC) in advanced non-small cell lung cancer (NSCLC)Nick Thatcher
CRC Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
Lung Cancer 38:S71-3. 2002
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Nick Thatcher
Medical Oncology, Christie Hospital NHS Trust, Manchester M20 4BX, UK
Lancet 366:1527-37. 2005..This placebo-controlled phase III study investigated the effect on survival of gefitinib as second-line or third-line treatment for patients with locally advanced or metastatic non-small-cell lung cancer...
- Expert consensus on the management of erlotinib-associated cutaneous toxicity in the u.kNicholas Thatcher
Department of Medical Oncology, Manchester, M20 4BX, UK
Oncologist 14:840-7. 2009..K., certain parts were modified. The resulting expert opinion is a practical and workable version of the international proposal that considers all applicable national issues regarding the management of erlotinib-associated skin toxicity...
- Sequential platinum-based chemotherapy-thoracic radiotherapy in early stage non-small cell lung cancerNick Thatcher
CRC Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 9BX, United Kingdom
Clin Cancer Res 11:5051s-5056s. 2005....
- Integrating new targeted agents into the treatment of non-small-cell lung cancerNick Thatcher
Christie and Wythenshawe Hospitals, Manchester, UK
Lung Cancer 54:S25-31. 2006....
- Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancerRichard Booton
Christie Hospital NHS Trust, Manchester, United Kingdom
J Thorac Oncol 1:679-83. 2006....
- Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trialRovel Colaco
Department of Clinical Oncology, the Christie NHS Foundation Trust, Manchester, UK
Lung Cancer 76:72-7. 2012..Routine ENI omission will be further evaluated prospectively in the ongoing phase III CONVERT trial (NCT00433563)...
- Perspectives on novel therapies for bronchial carcinomaFiona Blackhall
Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX, UK
Expert Opin Pharmacother 6:1157-67. 2005..In this article the recent and ongoing Phase II and III trials of these therapies in lung cancer are summarised, and the prospects for their further clinical development are discussed...
- Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trialHamid Sheikh
Dept of Clinical Oncology, the Christie NHS Foundation Trust, Manchester, UK
Lung Cancer 74:75-9. 2011....
- Gefitinib for the treatment of non-small-cell lung cancerLynn Campbell
Christie Hospital NHS Foundation Trust, Medical Oncology, Wilmslow Road, Manchester, UK
Expert Opin Pharmacother 11:1343-57. 2010..Recent trials of the small-molecule EGFR inhibitor gefitinib have now more clearly defined indications for usage, and clinical and molecular factors predictive of benefit...
- Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancerRichard Booton
Christie Hospital National Health Service Trust, Manchester, United Kingdom
Cancer 106:2421-7. 2006..The authors investigated the relation between XPD polymorphisms and treatment response, toxicity, and overall survival in patients who received platinum-based chemotherapy for advanced nonsmall cell lung cancer (NSCLC)...
- Chemotherapy for advanced non-small cell lung cancer patients with performance status 2Fiona H Blackhall
Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK
Curr Opin Oncol 17:135-9. 2005..In this article, we focus on the available literature for patients with a PS of 2, in whom a role for chemotherapy has yet to be defined...
- Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinomaSarah Danson
Department of Medical Oncology, Christie Hospital National Health Service Trust, Manchester, United Kingdom
Cancer 98:542-53. 2003..The primary objective was survival. Secondary objectives were time to disease progression, response rates, evaluation of toxicity, disease-related symptoms, World Health Organization performance status (PS), and quality of life (QoL)...
- The place of targeted therapy in the patient management of non-small cell lung cancerNicholas Thatcher
Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M204BX, UK
Lung Cancer 57:S18-23. 2007..However, these are preliminary data and further research is required to clarify the role of targeted therapies in the management of advanced NSCLC...
- Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small cell lung cancerNicholas Thatcher
Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, United Kingdom
Oncologist 15:1034-42. 2010....
- Erlotinib in non-small cell lung cancer: a reviewFiona H Blackhall
Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
Expert Opin Pharmacother 6:995-1002. 2005..This paper reviews the pharmacology, preclinical and clinical data to support the use of erlotinib in NSCLC...
- First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global viewNicholas Thatcher
Division of Cancer Studies, Faculty of Medical and Human Sciences, University of Manchester, Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX, UK
BMC Proc 2:S3. 2008..This combination therapy has provided promising results which should be confirmed in future studies...
- Chemotherapy in advanced nonsmall cell lung cancer: indication, intensity, and durationRichard Booton
CRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom
Curr Opin Oncol 14:191-8. 2002..The evidence suggests that dose intensification is a useful tool, and that its use in combination with markers of treatment duration and cumulative dose may help to maximize results from current active drug combinations...
- New drugs in small cell lung cancerNicholas Thatcher
CRC Department of Medical Oncology, Christie and Wythenshawe Hospitals, Manchester, UK
Suppl Tumori 1:S26-7. 2002
- Lung cancer after treatment for Hodgkin's lymphoma: a systematic reviewPaul Lorigan
Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Manchester M20 4BX, UK
Lancet Oncol 6:773-9. 2005..The role of screening in this group of patients has not yet been assessed, but an international study combining CT with genomic and proteomic assessment is planned...
- Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancerFred R Hirsch
Division of Medical Oncology, University of Colorado Cancer Center, Aurora, CO 80045, USA
Cancer 112:1114-21. 2008..Two different antibodies, scoring systems, and cutoff points of epidermal growth factor receptor (EGFR) protein expression were compared to predict response and survival of enrolled patients...
- Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. IntroductionPaul A Bunn
University of Colorado Cancer Center, Aurora, Colorado, USA
Oncologist 13:1-4. 2008..In fact, many commonly used chemotherapeutic drugs have antiangiogenic activity. Ongoing studies are focusing on patient selection and targeted therapies, and there are many new agents undergoing clinical trials...
- Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. ConclusionPaul A Bunn
University of Colorado Cancer Center, Aurora, Colorado, USA
Oncologist 13:37-46. 2008....
- Quality-of-life assessment in advanced lung cancer: considerations for evaluation in patients receiving chemotherapyRichard J Gralla
New York Lung Cancer Alliance, New York, NY 10024, USA
Lung Cancer 46:S41-7. 2004..Important goals include building on these results by including quality-of-life assessment in all major clinical trials, and demonstrating feasible ways to incorporate this evaluation into daily clinical practice...
- Second-line treatment of advanced non-small cell lung cancerCesare Gridelli
Medical Oncology, S G Moscati Hospital, Avellino, Italy
J Thorac Oncol 3:430-40. 2008..Further research is mandatory, to find better treatments, and to identify clinical and molecular predictive markers of efficacy, both for chemotherapy and for novel biologic agents...
- Management of unresectable stage III non-small-cell lung cancer with combined-modality therapy: a review of the current literature and recommendations for treatmentNeil A Bayman
Department of Clinical Oncology, Christie Hospital, Manchester, UK
Clin Lung Cancer 9:92-101. 2008..The potential role of novel and targeted therapies and radiation dose escalation is also considered. Finally, recommendations are made for the treatment of unresectable stage III NSCLC...
- Targeting blood vessels for the treatment of non-small cell lung cancerEthan Amir
Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom
Curr Cancer Drug Targets 8:392-403. 2008....
- Novel therapies for the treatment of small-cell lung cancer: a time for cautious optimism?Ruth E Board
Cancer Research UK Department Medical Oncology, Christie Hospital, Manchester, UK
Drugs 66:1919-31. 2006..Trials with the immunoconjugate BB-10901 and temirolimus are ongoing...
- Palliative treatmentSofia Baka
Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX UK
Hematol Oncol Clin North Am 18:417-32. 2004
- Targeted molecular mechanisms of epoetin alfaCorey J Langer
Department of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
Lung Cancer 41:S133-45. 2003..Future research needs to be conducted to explore the potential for epoetin alfa to improve survival time in lung cancer patients...
- Modern management of small-cell lung cancerRoberta Ferraldeschi
Christie Hospital NHS Foundation Trust, Manchester, UK
Drugs 67:2135-52. 2007..The challenge for the future is to identify new targets, overcome drug-resistance mechanisms and redundancy in biological systems, and incorporate these new treatments into concurrent chemo-radiotherapy schedules...
- ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancerRichard Booton
Christie Hospital NHS Trust and Paterson Institute for Cancer Research, Manchester, United Kingdom
J Thorac Oncol 2:902-6. 2007..We sought to determine the influence of ERCC1 mRNA expression in advanced NSCLC on chemotherapy response, toxicity, and survival after platinum-based chemotherapy...
- Cost effectiveness of increasing the dose intensity of chemotherapy with granulocyte colony-stimulating factor in small-cell lung cancer: based on data from the Medical Research Council LU19 trialLaura Bojke
Centre for Health Economics, University of York, York, England
Pharmacoeconomics 24:443-52. 2006..However, given its acquisition cost, it is important to assess its cost effectiveness within a resource-constrained health service...
- Where next for gefitinib in patients with lung cancer?Fiona Blackhall
Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust Manchester, M20 4BX, UK
Lancet Oncol 7:499-507. 2006..Here, we review the clinical experience with gefitinib and, in light of the licensing of erlotinib, address the lessons learned, the ongoing trials, and whether scope remains for clinical development of gefitinib in selected patients...
- Thoracic radiation therapy for limited-stage small-cell lung cancer: unanswered questionsCorinne Faivre-Finn
Clinical Oncology Department, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK
Clin Lung Cancer 7:23-9. 2005..These trials should integrate translational research studies to investigate the molecular basis of RT resistance and to develop biomarker profiles of prognosis...
- Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II studyGiuseppe Giaccone
Department of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
Clin Cancer Res 12:6049-55. 2006..Erlotinib has proven activity in pretreated patients with advanced non-small cell lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC and assessed biological predictors of outcome...
- Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancerFred R Hirsch
University of Colorado Cancer Center, PO Box 6511, Mail Stop 8111, Aurora, CO 80045, USA
J Clin Oncol 24:5034-42. 2006..We analyzed ISEL tumor biopsy samples to examine relationships between biomarkers and clinical outcome after gefitinib treatment in a placebo-controlled setting...
- Early stage lung cancer--new approaches to evaluation and treatment: conference summary statementThomas J Lynch
Division of Hematology Oncology and Dana Farber Partners Cancer Care, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA
Clin Cancer Res 11:4981s-4983s. 2005
- Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panelCesare Gridelli
Division of Medical Oncology, S G Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy
Crit Rev Oncol Hematol 63:53-64. 2007..A special focus is dedicated to neutropenia and the use of CSFs in the treatment of the three "big killers" among the solid tumours: breast cancer, lung cancer and colorectal cancer...
- Options for first- and second-line therapy in small cell lung cancer--a workshop discussionNick Thatcher
University of Manchester and Christie Hospital, Manchester, UK
Lung Cancer 41:S37-41. 2003..The potential role of combination therapy with topotecan/temozolomide, both of which cross the blood-brain barrier, is currently being investigated...
- Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL studyAlex Chang
Johns Hopkins Singapore International Medical Centre, Singapore
J Thorac Oncol 1:847-55. 2006....
- Standard versus dose-intensified chemotherapy with sequential reinfusion of hematopoietic progenitor cells in small cell lung cancer patients with favorable prognosisErika Buchholz
Department of Surgery and Interdisciplinary Thoracic Oncology, Klinikum Mannheim, Mannheim, Germany
J Thorac Oncol 2:51-8. 2007..The combination of ifosfamide, carboplatin, and etoposide (ICE) is highly effective in treating small cell lung cancer (SCLC). Myelosuppression resulting in leukopenia and thrombocytopenia is the dose-limiting toxicity...
- Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trialRoberta Ferraldeschi
Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK
Expert Rev Anticancer Ther 7:635-40. 2007..An interim analysis will be conducted after 700 patients have been enrolled. The study will also use pharmacogenomic analysis to evaluate biological predictors of response, in particular to pemetrexed...
- Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancerPaul Lorigan
Weston Park Hospital, Sheffield, UK
J Natl Cancer Inst 97:666-74. 2005....
- Clinical experience with gefitinib in Indian patientsPurvish Parikh
Tata Memorial Hospital, Mumbai, India
J Thorac Oncol 3:380-5. 2008..Increased responsiveness to gefitinib has been demonstrated in particular subsets of patients, for example never smokers and patients of Asian origin. However, to date, little is known of its use specifically in patients from India...
- Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trialMartin F Muers
Leeds General Infirmary, Leeds, UK
Lancet 371:1685-94. 2008..We investigated whether the addition of chemotherapy to ASC improved survival and quality of life...